Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis.

The transforming growth factor-beta (TGF-beta) receptor complex and its downstream signaling intermediates constitute a tumor suppressor pathway. In many cancers, expression of TGF-beta type II receptor (TbetaR-II) is markedly decreased. In the present study, we show that the hepatocytes isolated from 15-day-old, but not 9-month-old, mice heterozygous for the deletion of the TbetaR-II gene are slightly less sensitive to the growth-inhibitory effect of TGF-beta when compared with wild-type littermates of same age. In addition, the proliferation index of hepatocytes as indicated by bromodeoxyuridine incorporation is mildly increased in the heterozygous mice. These subtle changes in cellular phenotype did not result in either gross or microscopic abnormality of the liver. The treatment of these mice with the chemical carcinogen, diethylnitrosamine, results in a significantly enhanced tumorigenesis in the liver when compared with the wild-type littermates. Our results demonstrate the gene-dosage effect of TbetaR-II and indicate that the reduced expression of TbetaR-II in mice increases susceptibility to tumorigenesis in the liver.

[1]  S. Markowitz,et al.  Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis , 2000 .

[2]  C. Day,et al.  Inhibition of rat hepatocyte proliferation by transforming growth factor β and glucagon is associated with inhibition of ERK2 and p70 S6 kinase , 1999, Hepatology.

[3]  L. Wakefield,et al.  Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency , 1998, Nature Medicine.

[4]  Y. Nagamachi,et al.  Absence of mutations in the analysis of coding sequences of the entire transforming growth factor-beta type II receptor gene in sporadic human breast cancers. , 1998, Oncology reports.

[5]  Y. Mizobuchi,et al.  Suppressive effect of oestradiol on chemical hepatocarcinogenesis in rats , 1998 .

[6]  K. Miyazono,et al.  Loss of expression of transforming growth factor beta type I and type II receptors correlates with tumor grade in human prostate cancer tissues. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  K. Kinzler,et al.  Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. , 1995, Science.

[8]  M. Sporn,et al.  Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Jeffrey L. Wrana,et al.  Mechanism of activation of the TGF-β receptor , 1994, Nature.

[10]  K. Miyazono,et al.  Cloning of a TGFβ type I receptor that forms a heteromeric complex with the TGFβ type II receptor , 1993, Cell.

[11]  R. Weinberg,et al.  Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase , 1992, Cell.

[12]  Anita B. Roberts,et al.  Peptide Growth Factors and Their Receptors I , 1990, Springer Study Edition.

[13]  M. Sporn,et al.  Transforming growth factor-beta 1: histochemical localization with antibodies to different epitopes , 1989, The Journal of cell biology.

[14]  J. Massagué TGF-beta signal transduction. , 1998, Annual review of biochemistry.

[15]  M. J. Ravitz,et al.  Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. , 1997, Advances in cancer research.

[16]  Chung Lee,et al.  Genetic change in transforming growth factor β (TGF-β) receptor type I gene correlates with insensitivity to TGF-β1 in human prostate cancer cells , 1996 .